New drug hopes to tame hardening skin disease
NCT ID NCT06210945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called CM-101 for people with systemic sclerosis, a disease that causes skin hardening and organ damage. About 45 adults will receive either the drug or a placebo to check safety and how well the body tolerates it. The goal is to see if CM-101 can reduce disease activity and inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts